EGFR Test Your Knowledge

Test Your Knowledge

Quiz: Most EGFR+ Lung Cancer Mutations are Which of the Following?

01/28/2022

Almost all EGFR+ lung cancers are ________.

Almost all EGFR+ lung cancers...

01/28/2022

Oncology

Test Your Knowledge

Quiz: What is the Effect of Smoking History in EGFR-Mutated NSCLC?

09/13/2021

True or false: EGFR-mutant NSCLC mainly occurs in non-smoking patients, but most series report 10% of cases in current of previous smokers.

True or false: EGFR-mutant NSCLC...

09/13/2021

Oncology

Test Your Knowledge

Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?

08/03/2021

The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.

The combination of...

08/03/2021

Oncology

Test Your Knowledge

Quiz: Are CAR T-Cells Active Against EGFR+ Hypopharyngeal Carcinoma?

08/17/2020

True or False: EGFR-CAR T-cells produce anti-tumor activity in EGFR-positive hypopharyngeal carcinoma.

True or False: EGFR-CAR T-cells...

08/17/2020

Oncology

Test Your Knowledge

Quiz: A Potential Combo Therapy for EGFR-Positive, MET-Amplified NSCLC

04/13/2020

True or False: Researchers posit osimertinib plus savolitinib as a potential combo therapy for MET-amplified, EGFR-positive, advanced NSCLC that progressed with EGFR TKIs.

True or False: Researchers posit...

04/13/2020

Oncology

Test Your Knowledge

Quiz: Erlotinib With or Without Bevacizumab for Advanced EGFR-Positive NSCLC

10/29/2019

True or False: PFS rates with erlotinib therapy plus bevacizumab were superior to erlotinib alone for EGFR-positive NSCLC.

True or False: PFS rates with...

10/29/2019

Oncology

Test Your Knowledge

Quiz: Bevacizumab–Erlotinib Combo vs Erlotinib Alone for EGFR-Positive NSCLC

05/06/2019

True or false: In a recent trial, combining bevacizumab therapy with erlotinib improved progression-free survival over erlotinib alone in patients with EGFR-positive NSCLC.

True or false: In a recent...

05/06/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology